Synthesis of ω-(7-aryl-8-oxo-7,8-dihydro[1,2,4]-triazolo-[4,3-a]pyrazin-3-yl)alkylcarboxylic acids and their amides as perspective pharmaceutical agents
Keywords:3-hydrazinopyrazin-2(1H)-one, [1, 2, 4]triazolo[4, 3-a]pyrazin-8(7H)-one, succinic anhydride, glutaric anhydride, cyclization, amide formation
AbstractPreviously designated a comfortable and effective scheme of 3,7-disubstituted [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-ones synthesis was spread to derivatives of ω-(7-aryl-8-oxo-7,8-dihydro[1,2,4]triazolo[4,3-a]pyrazin-3-yl) alkylcarboxylic acids. Our approach consists of application of reaction of formerly described 3-hydrazinopyrazin-2-ones with cyclic anhydrides of dicarbonic acids such as succinic and glutaric anhydrides. Consequent cyclization was carried out in DMFA by means of boiling during 12 hours and resulted in creation of 3-(7-aryl-8-oxo-7,8-dihydro[1,2,4]triazolo[4,3-a]pyrazin-3-yl)propanoic acids or 4-(7-aryl-8-oxo-7,8-dihydro[1,2,4]triazolo[4,3-a]pyrazin-3-yl) butanoic acids with yield 51 – 65%. To obtain amides we used activation of carboxylic group of obtained acids by means of application of carbonilmidiimidazolamide along with anhydrous dioxane with intermidiate creation of imidazolilamide, subsequent reaction with both of aliphatic and aromatic amines was carried out by means of boiling for 12 hours. Yield of obtained amides was approxiametely 50 – 92%. The structure of obtained compounds was proved by means of elemental analysis and 1H NMR spectroscopy data. The synthesized compounds are of certain interest as potential pharmacologic agents associated with the regulation of lipid metabolism and ability of these compounds to have an impact on the level of lipoproteins, purine metabolism and receptivity of tissues to glucose.
Doukhan G., Huynh Dinh Tam, Bisagni E. et al. // J. Med. Chem. – 1979. – Vol. 14, №4. – P. 375–380.
Kovalenko S.S., Kulikovska K.Yu., Drushlyak O.G. et al. // Chem. of Het. Compounds. – 2014. – №8. – Р. 1243–1249.
Koyama G., Umezawa H. // J. of Antibiotics. – 1965. – № 18A. – Р. 175–177.
Kulikovska K.Yu., Kovalenko S.S., Drushlyak O.G. et al. // ЖОрФХ. – 2014. – Vol. 12, №2 (46). – Р. 32–35.
Kulikovska K.Yu., Kovalenko S.S., Drushlyak O.G. et al. // Фармация Казахстана. – 2014. – № 9. – Р. 55–57.
Orechovich V.N. Institute of Biomedical Chemistry. PASS: http://www.pharmaexpert.ru/PASSOnline/.
Pat. US 2013/0196986 A1. Triazolopyrazinones as P2X7 receptor antagonists / M. Labroli, M. F. Czarniecki, C. S. Poker; applicant Merck Sharp & Dohme. – № EP2619204 A4; st. 16.09.2011; app. 20.03.2013.
Sarfati R. S., Gouyette C., Igolen J. et al. // J. Org. Chem. – 1979. – №44 (7). – Р. 1028–1035.
Sarges R., Howard H.R., Browne R.G. et al. // J. of Med. Chem. – 1990. – Vol. 33, № 8. – P. 2240–2254.
Zhou J., Yang M., Schneller S. W. // Tetrahedron. – 2004. – № 45. – Р. 8233–8234.
Copyright (c) 2016 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).